Study Title and Description
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
Key Questions Addressed
|7||Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?|
|8||Key Question 8. What are the harms of currently recommended antiviral treatments?|
Primary Publication Information
|Title||Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.|
|Author||Kowdley KV., Lawitz E., Poordad F., Cohen DE., Nelson DR., Zeuzem S., Everson GT., Kwo P., Foster GR., Sulkowski MS., Xie W., Pilot-Matias T., Liossis G., Larsen L., Khatri A., Podsadecki T., Bernstein B.|
|Country||From the Digestive Disease Institute, Virginia Mason Medical Center, Seattle (K.V.K.); Texas Liver Institute, University of Texas Health Science Center, San Antonio (E.L., F.P.); AbbVie, North Chicago (D.E.C., W.X., T.P.-M., G.L., L.L., A.K., T.P., B.B.); University of Florida College of Medicine, Gainesville (D.R.N.); J.W. Goethe University, Frankfurt, Germany (S.Z.); University of Colorado Denver, Aurora (G.T.E.); Indiana University, Indianapolis (P.K.); Queen Mary, University of London, Barts Health, London (G.R.F.); and Johns Hopkins University, Baltimore (M.S.S.).|
Pubmed ID: 24428468
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-9
Results & Comparisons
No Results found.